Efficacy and safety of Peginterferon alfa-2b plus Ribavirin for HCV-positive mixed cryoglobulinemia: A multicentre open-label study

Clinical and Experimental Rheumatology

Volumn 29, Issue 6, 2011, Pages 933-941

  Mazzaro, Cesare ^a   Monti, Giuseppe ^b   Saccardo, Francesco ^b   Zignego, Anna Linda ^c   Ferri, Clodoveo ^d   De Vita, Salvatore ^e   Gabrielli, Armando ^f   Lenzi, Marco ^g   Donada, Carlo ^h   Galli, Massimo ⁱ   Pietrogrande, Maurizio ⁱ   Pozzato, Gabriele ^j  

^a Pordenone General Hospital   (Italy)

^b Ospedale di Saronno   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Ospedale Civile di Gorizia   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF TRIESTE   (Italy)

more..

Author keywords

Antiviral therapy; Cryoglobulinemia glomerulonephritis; HCV genotype; Hepatitis C virus; Mixed cryoglobulinemia

Indexed keywords

PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84857518746     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. TEOH NC, FARRELL GC, CHAN HL: Individualisation of antiviral therapy for chronic hepatitis C. J Gastroenterol Hepatol 2010;25:1206-16.
2. HORSMANS Y: Treatment of chronic hepatitis C in elderly patients. Expert Opin Pharmacother 2010;11:571-7.
3. MALLET V, VALLET-PICHARD A, POL S: New trends in hepatitis C management. Presse Med 2010;39:446-51.
4. SINGAL AK, ANAND BS: Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials. J Clin Gastroenterol 2010;44:583-7.
5. FERRI C: Mixed cryoglobulinemia. Orphanet J Rare Dis 2008;3:25.
6. VASSILOPOULOS D, MANOLAKOPOULOS S: Rheumatic manifestations of hepatitis. Curr Opin Rheumatol 2010;22:91-6.
7. CRAXÌ A, LAFFI G, ZIGNEGO AL: Hepatitis C vims (HCV) infection: a systemic disease. Mol Aspects Med 2008;29:85-95.
8. FERRI S, MURATORI L, LENZI M, GRANITO A, BIANCHI FB, VERGANI D: HCV and autoimmunity. Curr Pharm des 2008;14:1678-85. (Pubitemid 351998592)
9. SANSONNO L, TUCCI FA, SANSONNO S, LAU-LETTA G, TROIANI L, SANSONNO D: B cells and HCV: an infection model of autoimmunità. Autoimmun Rev 2009;9:93-4.
10. ADINOLFI LE, UTILI R, ATTANASIO V, ZAMPINO E, RAGONE MF, TRIPODI G: Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinemia in hepatitis C virus patients: a prospective study. It J Gastroenterol 1996;28:1-9. (Pubitemid 26079760)
11. TANAKA K, AIYAMAT, IMAI J: Serum cryoglobulin and chronic hepatitis C virus disease among Japanese patients. Am J Gastroenterol 1995;90:1847-52.
12. POZZATO G, BURRONE O, BABA K et al.: Ethnic difference in the prevalence of monoclonal B-cell proliferation in patients affected by hepatitis C virus chronic liver disease. J Hepatol 1999;30:990-4. (Pubitemid 29278741)
13. MCCOLL MD, SINGER IO, TAIT RC, MCNEIL IR, CUMMING RL, HOGG RB: The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma-a regional association? Leuk Lymphoma 1997;26:127-30. (Pubitemid 27351016)
14. DAMMACCO F, SANSONNO D, PICCOLI C, TUCCI FA, RACANELLI V: The cryoglobulins: an overview. Eur J Clin Invest 2001;31:628-38. (Pubitemid 32642895)
15. BEDOSSA P, POYNARD T: An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93. (Pubitemid 26260021)
16. MAZZARO C, ZORAT F, CAIZZI M et al.: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632-8.
17. MAZZARO C, ZORAT F, COMAR C et al.: Interferon plus ribavirin in patients affected by hepatitis C virus positive mixed cryoglobulinemia resistant to previous interferon treatment (s). J Rheumatol 2003;30:1775-81. (Pubitemid 36962454)
18. ZIGNEGO AL, FERRI C, GIANNINI C et al.: Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996;1:31-4. (Pubitemid 26019622)
19. MICHITAKA K, DURAZZO M, TILLMANN HL, WALKER D, PHILIPP T, MANNS MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994;106:1603-10. (Pubitemid 24163133)
20. MANNS MP, MCHUTCHINSON JG, GORDON SC et al.: PEG-interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001;358:958-65. (Pubitemid 32913521)
21. FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
22. HADZIYANNIS SJ, SETTE HJR, MORGAN TR et al.: PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
23. rd Probe Investigators Meeting Venice 2008.
24. SAADOUN D, RESCHE-RIGON M, THIBAULT V, PIETTE JC, CACOUB P: Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis Rheum 2006;54:3696-706. (Pubitemid 44737183)
25. CACOUB P, LIDOVE O, MAISONOBE T et al.: Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-26. (Pubitemid 35453543)
26. FABRIZI F, LUNGHI G, MESSA P, MARTIN P: Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008;21:813-25.
27. RIZZA P, MORETTI F, BELARDELLI F: Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010;43:204-9.
28. LAMPRECHT P, MOOSIG F, GAUSE A et al.: Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2001;60:385-90. (Pubitemid 32242753)
29. SUGIMURA T, MOTOMURA S, SAKAI H, NAWATA H: Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C. Hepatogastroenterology 1999;46:1827-30. (Pubitemid 29366355)
30. DI CESARE E, SPADARO A, AJELLO A et al.: Soluble CD30 serum levels before and after treatment with alpha-interferon in patients with chronic hepatitis C. Clin Chem Lab Med 2005;43:823-6. (Pubitemid 41461156)
31. LIAO YR, YEN CP, LIN CC, FU LS, CHIU CC, CHI CS: Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient. J Microbiol Immunol Infect 2004;37:67-70.
32. HALFON P, BOURLIÈRE M, OUZAN D et al.: Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol 2008;46:2106-8. (Pubitemid 351831855)
33. PHAM TN, MACPARLAND SA, MULROONEY PM, COOKSLEY H, NAOUMOV NV, MICHA-LAK TI: Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004;78:5867-74. (Pubitemid 38661674)
34. RADKOWSKI M, GALLEGOS-OROZCO JF, JABLONSKA J et al.: Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-14. (Pubitemid 40066388)
35. TARANTINO A, CAMPISE M, BANFI G et al.: Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23.
36. FERRI C, SEBASTIANI M, GIUGGIOLI D et al.: Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74. (Pubitemid 38887136)
37. ALRIC L, PLAISIER E, THEBAULT S et al.: Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617-23. (Pubitemid 38401876)
38. BRUCHFELD A, LINDAHL K, STAHLE L, SODERBERG M, SCHVARCZ R: Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80. (Pubitemid 36939631)
39. JOHNSON RJ, GRETCH DR, YAMABE H et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70. (Pubitemid 23056436)
40. ROSSI P, BERTANI T, BAIO P et al.: Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003;63:2236-41. (Pubitemid 36605837)
41. SANSONNO D, DE RE V, LAULETTA G et al.: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon with an anti-CD20. Blood 2003;101:3818-26. (Pubitemid 36857852)
42. DELLA ROSSA A, BALDINI C, TAVONI A, BOMBARDIERI S: How HCV has changed the approach to mixed cryoglobulinemia. Clin Exp Rheumatol 2009;27(Suppl. 52): S115-23.
43. QUARTUCCIO L, PETRARCA A, MANSUTTI e et al.: Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 2010;28(Suppl. 57):84-7.
44. ROCCATELLO D, BALDOVINO S, ROSSI D et al.: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61. (Pubitemid 40057628)
45. QUARTUCCIO L, SOARDO G, ROMANO G et al.: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842-6. (Pubitemid 43985372)
46. PETRARCA A, RIGACCI L, CAINI P et al.: Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-42.
47. TERRIER B, SAADOUN D, SÈNE D et al.: Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009;60:2531-40.
48. SAADOUN D, RESCHE RIGON M, SENE D et al.: Rituximab plus Peg-interferon-/ribavirin compared with Peg-interferon-/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34.
49. DAMMACCO F, TUCCI FA, LAULETTA G et al.: Pegylated interferon-, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-53.
50. BACON BR, GORDON SC, LAWITZ e et al.: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
51. MCHUTCHISON JG, MANNS MP, MUIR AJ et al.: Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.